Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) and Tharimmune (NASDAQ:THAR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, profitability, earnings, dividends and valuation.
Volatility and Risk
Ventyx Biosciences has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Ventyx Biosciences and Tharimmune, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ventyx Biosciences | 1 | 0 | 4 | 0 | 2.60 |
| Tharimmune | 1 | 0 | 1 | 1 | 2.67 |
Insider and Institutional Ownership
97.9% of Ventyx Biosciences shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 14.5% of Ventyx Biosciences shares are owned by insiders. Comparatively, 25.6% of Tharimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Ventyx Biosciences and Tharimmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ventyx Biosciences | N/A | -48.11% | -43.89% |
| Tharimmune | N/A | -588.45% | -264.41% |
Valuation & Earnings
This table compares Ventyx Biosciences and Tharimmune”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ventyx Biosciences | N/A | N/A | -$135.12 million | ($1.50) | -6.66 |
| Tharimmune | N/A | N/A | -$12.20 million | ($3.99) | -0.64 |
Ventyx Biosciences is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.
Summary
Tharimmune beats Ventyx Biosciences on 7 of the 12 factors compared between the two stocks.
About Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
About Tharimmune
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
